based in demographic (gender, skin colour, age and marital status), socioeconomic (schooling and socioeconomic position) and lifestyle variables (smoking, physical inactivity, obesity and self-perception of health status). χ² Test was used for bivariate analyses and Poisson regression for multivariate analyses, with design effect adjustment.

**Results** Prevalence of aspirin use in primary prevention was 24.8% (95% CI 21.0 to 28.9) and 34.3% (95% CI 29.5 to 39.4) for secondary prevention. In primary prevention, aspirin use was higher in non-whites and older people and among those with worst self-perceived health. For secondary prevention, the highest aspirin use was reported by the oldest, wealthiest and formerly smoking people.

**Conclusion** Aspirin use prevalence was low in both primary and secondary prevention of cardiovascular diseases. Especially in secondary prevention, where there is no doubt about the indication of aspirin, the use of medication in this population was half of that found in the literature. Further studies are necessary to identify the causes for this low aspirin use for prevention of cardiovascular diseases.

**P2-314 RELATIVE BODY FAT AND BLOOD PRESSURE IN CHILDREN: A POPULATION BASED INDIVIDUALLY MATCHED STUDY IN CHINA**

J Wang,* 1 J Ma. 1 School of Medicine, University of Queensland, Brisbane, Queensland, Australia; 2 Institute of Child and Adolescent Health, Peking University Health Sciences, Beijing, China

**Introduction** Normative blood pressure (BP) percentiles in children recommended by the current guidelines vary with body size. Separating the effect of fat mass from that of total body size on BP is important but challenging because fat mass and body size are strongly correlated. The objective of this study is to assess the relationship of relative body fat and BP in children.

**Methods** Chinese children who had a high skinfold thickness were individually matched by age, sex, weight and height to an equal number of children with a low skinfold. Systolic and diastolic BP levels were compared between the high and low body fat groups.

**Results** 7066 pairs of children aged 7–18 years were obtained, including 3042 pairs of boys and 4024 pairs of girls. As a result of matching, the two groups had identical distributions of height, weight and body mass index. The difference between the high and low fat groups in systolic BP was small (0.03, 95% CI –0.29 to 0.36 mm Hg) and not statistically significant. Diastolic BP in the high body fat group was 0.68 (95% CI 0.40 to 0.96) mm Hg higher than that in the low body fat group.

**Conclusion** For a given body size as measured by height and weight, relative body fat has little impact on systolic BP levels in children. Systolic BP is driven by overall body size. The same amount of fat mass and lean mass may have a similar impact on blood pressure in children.

**P2-315 THE EFFECTIVENESS OF SYSTEMATIC SYMPTOM ASSESSMENT TO IMPROVE PATIENT CARE IN ONCOLOGY MEDICINE: A SYSTEMATIC REVIEW**

J Walker, S Wild,* University of Edinburgh, Edinburgh, UK

**Introduction** Socio-economic status (SES) is associated with both type 2 diabetes and cancer mortality and may confound their relationship.

**Methods** We performed a retrospective cohort study using a population-based national diabetes database for 35–84 year olds in Scotland for 2001–2007 and an area-based measure of SES. RR for mortality from lung, colorectal, breast and prostate cancer among people with type 2 diabetes compared to the population without diabetes were estimated using Poisson regression.

**Results** Complete data were available for 210,994 eligible people (99.4%). There were 2081 deaths from lung cancer, 945 from colorectal cancer, 525 from breast cancer and 419 from prostate cancer. Age adjusted RR (95% CI) for type 2 diabetes were 1.20 (1.12 to 1.29), 1.34 (1.22 to 1.47), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal, breast and prostate cancer were 0.93 (0.82 to 1.04), 1.35 (1.23 to 1.48), 0.97 (0.89 to 1.05), 1.34 (1.19 to 1.49), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal, breast and prostate cancer were 0.96, 1.33 (1.22 to 1.47), 0.97 (0.88 to 1.07) for men and 1.03 (0.91 to 1.17), 1.34 (1.20 to 1.50), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal, breast and prostate cancer were 0.98 (0.90 to 1.07) for men. Age and SES adjusted RR (95% CI) for lung, colorectal and breast cancer were 0.95 (0.82 to 1.04), 1.35 (1.23 to 1.48), 0.97 (0.89 to 1.05), 1.34 (1.19 to 1.49), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal and prostate or breast cancer were 0.93 (0.82 to 1.04), 1.35 (1.23 to 1.48), 0.97 (0.89 to 1.05) for men and 1.03 (0.91 to 1.17), 1.34 (1.20 to 1.50), 1.49 (1.35 to 1.65) for women.

**Conclusions** Type 2 diabetes was associated with higher mortality from colorectal cancer and breast cancer. Adjusting for SES had a small effect on RR for lung cancer but almost no effect for other cancers suggesting that SES is not an important confounder of the association between type 2 diabetes and mortality from common cancers.

**P2-316 RELATIVE MORTALITY FROM COMMON CANCERS AMONG PEOPLE WITH TYPE 2 DIABETES AND THE EFFECT OF SOCIO-ECONOMIC STATUS**

J Wang,* 1,2 R Viola. 1 Queen’s University, Kingston, Ontario, Canada; 2 Kingston General Hospital, Kingston, Ontario, Canada; 3 Hotel Dieu Hospital, Kingston, Ontario, Canada; 4 Queen’s Cancer Research Institute, Kingston, Ontario, Canada

**Introduction** Socio-economic status (SES) is associated with both type 2 diabetes and cancer mortality and may confound their association.

**Methods** We performed a retrospective cohort study using a population-based national diabetes database for 35–84 year olds in Scotland for 2001–2007 and an area-based measure of SES. RR for mortality from lung, colorectal, breast and prostate cancer among people with type 2 diabetes compared to the population without diabetes were estimated using Poisson regression.

**Results** Complete data were available for 210,994 eligible people (99.4%). There were 2081 deaths from lung cancer, 945 from colorectal cancer, 525 from breast cancer and 419 from prostate cancer. Age adjusted RR (95% CI) for type 2 diabetes were 1.20 (1.12 to 1.29), 1.34 (1.22 to 1.47), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal, breast and prostate cancer were 0.93 (0.82 to 1.04), 1.35 (1.23 to 1.48), 0.97 (0.89 to 1.05), 1.34 (1.19 to 1.49), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal and prostate or breast cancer were 0.95 (0.82 to 1.04), 1.35 (1.23 to 1.48), 0.97 (0.89 to 1.05), 1.34 (1.19 to 1.49), 1.49 (1.35 to 1.65) for women. Age and SES adjusted RR (95% CI) for lung, colorectal and prostate or breast cancer were 0.96, 1.33 (1.22 to 1.47), 0.97 (0.88 to 1.07) for men and 0.98 (0.90 to 1.05), 1.34 (1.19 to 1.49), 1.49 (1.35 to 1.65) for women.

**Conclusions** Type 2 diabetes was associated with higher mortality from colorectal cancer and breast cancer. Adjusting for SES had a small effect on RR for lung cancer but almost no effect for other cancers suggesting that SES is not an important confounder of the association between type 2 diabetes and mortality from common cancers.